<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Growth hormone insensitivity syndromes
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Growth hormone insensitivity syndromes
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Growth hormone insensitivity syndromes
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Erick J Richmond, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan D Rogol, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mitchell E Geffner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H12573222">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Growth hormone insensitivity (GHI) is a group of inherited disorders in which there is a reduction in or absence of the biologic effects of growth hormone (GH) despite normal or above normal production and secretion of GH. These disorders are characterized by growth failure and normal or increased circulating levels of GH, in contrast with GH deficiency. In addition, many affected individuals also have low circulating levels of GH-binding protein (GHBP; which is equivalent to the shed extracellular-binding domain of the GH receptor) and is measured in a commercially available clinical test reflecting the number of GH receptors. (See
         <a class="medical medical_review" href="/z/d/html/5842.html" rel="external">
          "Diagnosis of growth hormone deficiency in children"
         </a>
         .)
        </p>
        <p>
         The classic model of GHI is in patients with Laron syndrome, caused by mutations in the GH receptor gene. However, subsequent experience has shown that there is a spectrum of GHI caused by a variety of defects along the GH-insulin-like growth factor 1 (IGF-1) axis (
         <a class="graphic graphic_figure graphicRef80626" href="/z/d/graphic/80626.html" rel="external">
          figure 1
         </a>
         ). These disorders will be discussed in this topic review.
        </p>
        <p>
         A growing body of literature suggests that some patients with idiopathic short stature often have a component of GH resistance, which may call for alternative treatment approaches such as adjusting GH doses based on IGF-1 levels. These considerations are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5824.html" rel="external">
          "Growth hormone treatment for idiopathic short stature"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12573712">
         <span class="h1">
          PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         GHI can be caused by loss-of-function mutations in the growth hormone (GH) receptor gene or in its downstream mediators, the most important of which is insulin-like growth factor 1 (IGF-1). These syndromes are characterized by normal or elevated levels of GH and low levels of IGF-1 (except for IGF-1 receptor mutations, in which IGF-1 levels are normal or high) (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H12574092">
         <span class="h2">
          Growth hormone receptor mutations (Laron syndrome)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laron syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F262500&amp;token=87jLzclRwWxNoI%2BQq5Gg72anSRvNiFrekKts41X%2BuUGay6fJYOWKaJMDBsN%2FGG1U&amp;TOPIC_ID=15796" target="_blank">
          MIM #262500
         </a>
         ), the most common known cause of genetically mediated GHI, is characterized by severe postnatal growth failure [
         <a href="#rid1">
          1
         </a>
         ]. It is caused by homozygous or compound heterozygous mutations in the GH receptor gene; a variety of mutations have been identified, most of which affect the extracellular GH-binding region of the receptor [
         <a href="#rid2">
          2-4
         </a>
         ], while others affect the transmembrane and intracellular domains [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Patients with homozygous loss-of-function mutations in the GH receptor gene have severe growth failure, with a mean adult height in one report of 119 cm (47 inches) in females and 124 cm (49 inches) in males [
         <a href="#rid6">
          6
         </a>
         ]. However, there is wide variability in adult height, ranging in another series from -2.2 to -12 standard deviations (SD) [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         Other clinical features of Laron syndrome include small head circumference, characteristic facies with saddle nose and prominent forehead, delayed skeletal maturation, small genitalia and testes, short limb length compared with trunk length, and abnormal body composition, with osteopenia and obesity (
         <a class="graphic graphic_picture graphicRef80534" href="/z/d/graphic/80534.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_table graphicRef70163" href="/z/d/graphic/70163.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid9">
          9,10
         </a>
         ]. Intellectual development is normal or only modestly impaired. Unlike patients with IGF-1 deficiency (described below), there is minimal disturbance of prenatal growth.
        </p>
        <p>
         Patients with Laron syndrome also have metabolic abnormalities including hyperlipidemia and episodes of hypoglycemia, especially during infancy. Data are conflicting on the risk of insulin resistance. An Ecuadorian cohort displays less insulin resistance and lower rates of diabetes than relatives without Laron syndrome, despite higher percentage of body fat [
         <a href="#rid11">
          11,12
         </a>
         ]. On the other hand, reports from an Israeli cohort suggest increased risk for insulin resistance [
         <a href="#rid10">
          10,13,14
         </a>
         ]. Possible explanations for the apparent difference in diabetes among these two populations with Laron syndrome include differences in environment (lifestyle, diet, etc), differences in serum IGF-1 levels, differences in the specific GH receptor mutation, or differences in genetic risk for diabetes in their underlying gene pool. Understanding the differences in energy intake and expenditure may give insight to more fundamental aspects of energy balance.
        </p>
        <p>
         Moreover, individuals with Laron syndrome appear to have much lower cancer rates than healthy controls. Experimental evidence from animal models and in vitro studies suggest that the low levels of IGF-1 in Laron syndrome are responsible for the reduced susceptibility to cancer and for increased longevity [
         <a href="#rid11">
          11,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12574106">
         <span class="h2">
          Post-growth hormone receptor mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to GH receptor gene mutations, GHI can occur through mutations in the post-GH receptor signaling pathway. A number of mechanisms have been described and summarized in a review [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p class="headingAnchor" id="H4965236">
         <span class="h3">
          Abnormal growth hormone receptor signal transduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several patients have been described with GHI caused by a homozygous missense mutation in the gene encoding signal transducer and activator transcription 5B (
         <em>
          STAT5B
         </em>
         ) (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F245590&amp;token=87jLzclRwWxNoI%2BQq5Gg79INvKR9fkblv1BGAK9rybzoy4EjU%2Fn6f8y5gRX2IIJw&amp;TOPIC_ID=15796" target="_blank">
          MIM #245590
         </a>
         ), which is essential for normal signaling of the GH receptor [
         <a href="#rid17">
          17-20
         </a>
         ]. Patients with this condition have severe postnatal growth failure and immune dysregulation, which is probably because
         <em>
          STAT5B
         </em>
         also mediates signal transduction triggered by various immune ligands, such as interleukin-2 (IL-2), interleukin-4 (IL-4), and colony-stimulating factor 1 (CSF1) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         In various acquired conditions associated with growth failure, including malnutrition and inflammatory diseases, the relative GH resistance appears to be mediated by downregulation of STAT5B and Janus kinase 2 (JAK2) signaling [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12574578">
         <span class="h3">
          Defects of IGF-1 synthesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the gene encoding IGF-1 cause a unique syndrome of GHI (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F608747&amp;token=87jLzclRwWxNoI%2BQq5Gg7zWpdWaSm7wdhAtNvv8ruiYQBcZ0feCPu0I0NjX9ebkf&amp;TOPIC_ID=15796" target="_blank">
          MIM #608747
         </a>
         ) that overlaps with the phenotype of microcephalic primordial dwarfism. Complete absence of IGF-1 is probably lethal in humans, but individuals have been described with deletions in the insulin-like growth factor 1 gene (
         <em>
          IGF1
         </em>
         ) causing partial loss of function [
         <a href="#rid23">
          23-25
         </a>
         ].
        </p>
        <p>
         Unlike patients with GH receptor mutations (Laron syndrome), patients with
         <em>
          IGF1
         </em>
         gene mutations have prenatal growth failure, microcephaly, significant neurocognitive deficits, sensorineural hearing loss, and normal levels of IGFBP-3. These observations confirm that IGF-1 has an important role in fetal growth as well as brain development, whereas the role of GH during fetal development is less clear [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         One study found an association between idiopathic short stature and increased methylation of two promoter regions for the
         <em>
          IGF1
         </em>
         gene; these epigenetic changes are predicted to reduce the individual's sensitivity to GH [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5832.html" rel="external">
          "Causes of short stature", section on 'Idiopathic short stature'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12574660">
         <span class="h3">
          Defective transport/clearance of IGF-1
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another GHI syndrome is mediated by deficiency of the insulin-like growth factor-binding protein acid-labile subunit (IGFALS;
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615961&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz69hZ6jdICbGXvpm9jJJiwt&amp;TOPIC_ID=15796" target="_blank">
          MIM #615961
         </a>
         ). This protein is important for the stabilization of the IGF-1-IGFBP-3 complex, forming a three-part (ternary) complex in the circulation. Affected individuals usually have delayed onset of puberty and slow pubertal progression but only minimal slowing of linear growth [
         <a href="#rid27">
          27,28
         </a>
         ]. They have increased plasma levels of GH, normal levels of GH-binding protein (GHBP; the extracellular portion of the GH receptor), and very low levels of IGF-1 and IGFBP-3, which remain low after administration of recombinant GH.
        </p>
        <p>
         The human pregnancy-associated plasma protein A2 gene (
         <em>
          PAPPA2
         </em>
         ) encodes a metalloproteinase that cleaves IGFBP-3 and IGFBP-5. Mutations in the
         <em>
          PAPPA2
         </em>
         gene have been reported in patients with postnatal growth retardation with heights ranging from -1.0 to -3.8 SD (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F619489&amp;token=tEpDslnpc0F0kICl%2Fz7sFbbHsBJVAXU52QtjSlxi7cVJOMUG8nxa2VT29gYNsPhl&amp;TOPIC_ID=15796" target="_blank">
          MIM #619489
         </a>
         ) [
         <a href="#rid29">
          29
         </a>
         ]. Affected patients have elevated total serum IGF-1 levels (similar to those with IGF-1 resistance) but low serum free IGF-1 levels.
        </p>
        <p class="headingAnchor" id="H12574608">
         <span class="h3">
          IGF-1 resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the gene encoding the receptor for insulin-like growth factor 1 (IGF-1) have been reported in infants presenting with pre- and postnatal growth failure (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F270450&amp;token=87jLzclRwWxNoI%2BQq5Gg74NQeCwsRJ9R8yEphXZpgwQ%2FIJBrNG0q3WG0k%2BV%2BdUCe&amp;TOPIC_ID=15796" target="_blank">
          MIM #270450
         </a>
         ) [
         <a href="#rid30">
          30-32
         </a>
         ]. These mutations are thought to result in partial loss of function of the IGF-1 receptor, and the phenotype is variable with normal or only mildly abnormal cognitive development; some patients have microcephaly, sensorineural hearing loss, and insulin resistance that develops during adolescence. Unlike the other GHI syndromes, circulating levels of IGF-1 are normal or elevated. Since most affected patients are born small for gestational age, recombinant human GH treatment has been used; however, growth response is highly variable and close monitoring of serum IGF-1 levels is recommended [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H52899414">
         <span class="h3">
          Other conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several other genetic conditions associated with GHI have been identified:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In most patients with Noonan syndrome, short stature is mediated by constitutive activation of mitogen-activated protein kinases (MAPK) pathways and inhibition of STAT5b [
         <a href="#rid34">
          34
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased synthesis of GH receptors in Pygmies [
         <a href="#rid35">
          35
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disordered GH receptor degradation [
         <a href="#rid36">
          36
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities in the nuclear factor kappa-B (NFKB) pathway [
         <a href="#rid37">
          37
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12574025">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laron syndrome, characterized by severe GHI, has been reported in several hundred patients worldwide, the majority of whom have ancestry from the Mediterranean, Middle East, or South Asia regions, including a large cohort living in Ecuador [
         <a href="#rid8">
          8,38
         </a>
         ]. A history of consanguinity is common, consistent with an autosomal recessive pattern of inheritance. The other causes of GHI have been reported in few patients, so the epidemiology and geographical distribution is not clear. However, familial aggregation and a family history of consanguinity are still common.
        </p>
        <p class="headingAnchor" id="H12573705">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation of a child with short stature requires distinguishing between children with common nonpathologic causes such as constitutional delay of growth or familial short stature, those with a non-endocrine cause of growth failure (eg, Crohn disease), and those with an endocrine cause of short stature who might benefit from hormonal treatment. The general approach to this assessment is discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5834.html" rel="external">
          "Diagnostic approach to children and adolescents with short stature"
         </a>
         .)
        </p>
        <p>
         Evaluation of a child for GHI involves the following steps (
         <a class="graphic graphic_algorithm graphicRef112625" href="/z/d/graphic/112625.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suspect GHI in patients with severe growth failure (height &lt;-3 standard deviations [SD]) and low insulin-like growth factor 1 (IGF-1) levels. In young children, measurement of insulin-like growth factor-binding protein 3 (IGFBP-3) may be more informative. (See
         <a class="local">
          'IGF-1 and IGFBP-3'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclude causes of secondary IGF-1 deficiency, including undernutrition, hepatic disease, and growth hormone (GH) deficiency, through a focused clinical evaluation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supportive evidence may come from measuring basal GH concentrations and GH-binding protein (GHBP), or from the results of an IGF-1 generation test, which involves measuring the IGF-1 response to administered GH (but is not a standardized test for use in clinical practice). These tests may help to confirm the diagnosis and/or to indicate the level of the defect. Patients with post-GH receptor defects have distinct clinical and biochemical patterns (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Growth hormone concentration'
         </a>
         below and
         <a class="local">
          'Growth hormone-binding protein'
         </a>
         below and
         <a class="local">
          'IGF-1 generation test'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Confirm the diagnosis with molecular genetic testing, if available. The timing and selection of molecular testing depends upon the level of clinical suspicion (severity of growth failure and degree of reduction of IGF-1 and IGFBP-3 concentrations), as well as access to molecular testing. (See
         <a class="local">
          'Molecular testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4104587607">
         <span class="h2">
          IGF-1 and IGFBP-3
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a child with severe growth failure, low insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) concentrations suggest the possibility of GH deficiency and also GHI. However, interpretation of these tests requires caution:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In normal young children (&lt;3 years old), relatively low levels of IGF-1 are the norm, so this finding is not diagnostic of GH deficiency or GHI in this age group. Other causes of (transient) low IGF-1 levels include poor nutritional status, hypothyroidism, and renal failure, so these causes must be excluded to make the diagnosis of GHI. In normal children, IGF-1 levels rise two- to fourfold during puberty as a result of increased production during that time. IGF-1 and GH reach maximal levels around the time of peak height velocity [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Levels of IGFBP-3 may be more informative because they are less likely to vary with age, nutritional status, and chronic illness. IGFBP-3 is low in most of the GHI syndromes (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ). An exception is in patients with an insulin-like growth factor 1 gene (
         <em>
          IGF1
         </em>
         ) mutation, who have elevated IGFBP-3 levels, with low IGF-1 levels. This possibility should be considered in patients with severe prenatal growth failure. (See
         <a class="medical medical_review" href="/z/d/html/5842.html" rel="external">
          "Diagnosis of growth hormone deficiency in children", section on 'IGF-1 and IGFBP-3'
         </a>
         and
         <a class="local">
          'Defects of IGF-1 synthesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H711699142">
         <span class="h2">
          Growth hormone concentration
         </span>
         <span class="headingEndMark">
          —
         </span>
         A high basal GH level supports the diagnosis of GHI but is not diagnostic and should be interpreted with caution. A normal basal GH level is not suspicious for GHI unless the patient also has severe growth failure (height &lt;3 SD below the mean).
        </p>
        <p>
         Notably, most short patients with normal GH levels do
         <strong>
          not
         </strong>
         have one of these GHI syndromes and are classified as having idiopathic short stature rather than GHI. However, lesser degrees of GH resistance may play a role in idiopathic short stature (
         <a class="graphic graphic_figure graphicRef80626" href="/z/d/graphic/80626.html" rel="external">
          figure 1
         </a>
         ). Most of these patients with idiopathic short stature are not eligible for treatment with recombinant IGF-1 based on treatment recommendations, which are described below. Such patients may respond to GH therapy, but they may require adjustment of the GH dose to achieve therapeutic IGF-1 levels. These patients can be considered to have mild (partial) GHI, since levels of IGF-1 may rise to some degree after GH administration, but require doses higher than are typically used for treatment of GH deficiency [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5824.html" rel="external">
          "Growth hormone treatment for idiopathic short stature", section on 'Dose adjustment for IGF-1 levels'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2419898065">
         <span class="h2">
          Growth hormone-binding protein
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testing for GHBP can be used to further investigate the possibility of Laron syndrome, especially if molecular testing is not available. Testing for GHBP is commercially available.
        </p>
        <p>
         In patients with clinical characteristics of severe GHI and normal or elevated circulating GH levels, a low level of GHBP strongly supports a diagnosis of Laron syndrome, but normal levels are uninformative. This is because patients with Laron syndrome have low GHBP levels only if the GH receptor mutation affects the extracellular binding domain, but GHBP levels are normal or high if the GH receptor mutation affects the transmembrane or cytoplasmic domain of the GH receptor [
         <a href="#rid41">
          41,42
         </a>
         ]. GHBP levels also are normal in patients with GHI due to post-receptor defects.
        </p>
        <p class="headingAnchor" id="H3726085757">
         <span class="h2">
          Molecular testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who meet the clinical and laboratory parameters outlined above, we suggest testing for mutations in the genes that cause GHI. The first priority is testing for a mutation in the GH receptor gene (Laron syndrome) since this is the most common cause of GHI. Other tests can be selected as indicated by the clinical and biochemical profile (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ). These include evaluation for
         <em>
          IGF1
         </em>
         gene mutations in individuals with severe prenatal growth failure and elevated IGFBP-3 levels (see
         <a class="local">
          'Defects of IGF-1 synthesis'
         </a>
         above), or signal transducer and activator of transcription 5B (
         <em>
          STAT5B
         </em>
         ) gene mutations in patients who also have immunodeficiency (see
         <a class="local">
          'Abnormal growth hormone receptor signal transduction'
         </a>
         above). Testing that focuses on specific mutations is limited by the known causes of GHI.
        </p>
        <p>
         Specific testing for these mutations is available through some clinical laboratories, which are listed on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=15796" target="_blank">
          Genetic Testing Registry
         </a>
         website. Whole-exome sequencing (WES) also may be used and sometimes discovers mutations not identified by candidate-gene methods [
         <a href="#rid43">
          43,44
         </a>
         ]. However, interpretation of the WES results can be challenging since the pathogenicity of a novel variant is often unclear [
         <a href="#rid45">
          45
         </a>
         ]. Decisions about whether and how to perform molecular testing should be made by a specialist in these disorders. GH stimulation testing usually is not necessary, because the basal levels of GH are normal or high in patients with GHI, distinguishing them from individuals with GH deficiency. If GH stimulation testing is performed, the GH response to stimulation is usually robust.
        </p>
        <p class="headingAnchor" id="H266892585">
         <span class="h2">
          IGF-1 generation test
         </span>
         <span class="headingEndMark">
          —
         </span>
         If molecular testing is not available, an insulin-like growth factor 1 (IGF-1) generation test can be used to confirm the diagnosis of GHI and helps to predict responsiveness to recombinant IGF-1 therapy. This consists of a brief trial of GH administration for approximately one week. In patients with GHI, the low baseline IGF-1 will not rise after exogenous administration of GH for four to nine days [
         <a href="#rid10">
          10
         </a>
         ]. However, the protocols for performing this test have not been standardized, the levels of IGF-1 achieved are quite variable, and it may be difficult to obtain insurance authorization for the GH required for this short course of therapy [
         <a href="#rid41">
          41,46
         </a>
         ]. Therefore, this is not used routinely to evaluate patients with suspected GHI. Nonetheless, this test can be helpful in clarifying the diagnosis in conjunction with the clinical and other laboratory findings described above.
        </p>
        <p class="headingAnchor" id="H1886144131">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         GHI should be suspected in patients with severe growth failure (height &lt;-3 standard deviations [SD]) and low insulin-like growth factor 1 (IGF-1) and/or insulin-like growth factor-binding protein 3 (IGFBP-3) levels. Causes of secondary IGF-1 deficiency, including undernutrition, hepatic disease, and GH deficiency, should be excluded through a focused clinical evaluation.
        </p>
        <p>
        </p>
        <p>
         The diagnosis can be confirmed by molecular genetic testing for mutations in the GH receptor gene (Laron syndrome) or other genes that affect post-GH receptor signaling (
         <a class="graphic graphic_algorithm graphicRef112625" href="/z/d/graphic/112625.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Molecular testing'
         </a>
         above.)
        </p>
        <p>
         If molecular testing is not available, a clinical diagnosis of GHI can be made on the basis of a strong clinical phenotype and compatible biochemical testing (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ), ideally including supportive tests such as GH concentrations, GH-binding protein (GHBP), and/or an IGF-1 generation test. (See
         <a class="local">
          'IGF-1 generation test'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12573649">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment should be considered for patients with severe growth failure due to GHI whose epiphyses are open. Treatment should be started as soon as the GHI is identified for optimal effect. The approach to treatment depends on whether a specific cause of the GHI has been established and on the type of defect (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ). Treatment options include a trial of recombinant growth hormone (GH) or recombinant insulin-like growth factor 1 (IGF-1).
        </p>
        <p class="headingAnchor" id="H4219222800">
         <span class="h2">
          Trial of growth hormone
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with GHI and IGF-1 deficiency diagnosed by clinical criteria but not established by molecular testing, we suggest a trial of GH therapy for three to six months (
         <a class="graphic graphic_algorithm graphicRef112625" href="/z/d/graphic/112625.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid41">
          41
         </a>
         ]. Some of these children have partial GHI and may respond to GH if given at relatively high doses. Efficacy of GH is indicated by increased serum levels of IGF-1 (ideally into the upper one-half of the normal range) and increased height velocity (eg, increases the height velocity by at least 2.5 cm/year). (See
         <a class="medical medical_review" href="/z/d/html/5843.html" rel="external">
          "Treatment of growth hormone deficiency in children", section on 'Dose adjustment based on IGF-1 response'
         </a>
         .)
        </p>
        <p>
         If GH is effective, it is preferable to IGF-1. This is because GH is often more effective for patients with partial GHI, has a better safety profile (both short and longer term), and is more convenient. Children who do not respond to exogenous GH can then move on to IGF-1 treatment.
        </p>
        <p class="headingAnchor" id="H12573574">
         <span class="h2">
          Recombinant IGF-1
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Recombinant human insulin-like growth factor 1 (IGF-1;
         <a class="drug drug_general" data-topicid="9464" href="/z/d/drug information/9464.html" rel="external">
          mecasermin
         </a>
         ) is a recommended treatment for children with severe primary IGF-1 deficiency, whether due to mutations in the GH receptor, post-GH receptor signaling pathway, or
         <em>
          IGF1
         </em>
         gene [
         <a href="#rid41">
          41
         </a>
         ]. Accepted indications for treatment in this population are: two years of age or older with open epiphyses and height and basal IGF-1 standard deviations (SD) both ≤-3. It is contraindicated in patients with active or history of malignancy [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with proven gene defects that cause GHI can start directly on IGF-1 replacement [
         <a href="#rid41">
          41
         </a>
         ]; these include pathologic mutations in the GH receptor gene (Laron syndrome), signal transducer and activator of transcription 5B (
         <em>
          STAT5B
         </em>
         ) gene, or
         <em>
          IGF1
         </em>
         gene. Recombinant IGF-1 may also be used in children with primary GH deficiency due to a GHI gene deletion who have developed neutralizing antibodies during treatment with GH, causing an acquired GHI [
         <a href="#rid48">
          48,49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         IGF-1 replacement should not be used for patients with GHI due to established IGF-1 receptor gene mutations, as they are unlikely to respond. There is no known treatment for growth failure in these patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the cause of GHI has not been established, we suggest a trial of GH therapy before initiating IGF-1 replacement [
         <a href="#rid41">
          41
         </a>
         ]. This is because some patients with clinical features of GHI may respond to GH treatment. (See
         <a class="local">
          'Trial of growth hormone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and administration
         </strong>
         – Guidelines suggest starting recombinant human IGF-1 at a dose of 80 to 120 mcg/kg twice daily [
         <a href="#rid41">
          41
         </a>
         ]. The dose should be given 20 minutes after a carbohydrate-containing meal or snack to avoid hypoglycemia. The treatment is typically continued until height velocity has decreased to &lt;2 cm/year, which corresponds to closure or near-closure of the epiphyses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The effects of IGF-1 treatment on children with severe primary IGF-1 deficiency were examined in an open-label study of 76 children treated for up to 12 years [
         <a href="#rid49">
          49
         </a>
         ]. Height velocity increased from a mean of 2.8 cm/year at baseline to a mean of 8 cm/year during the first year of treatment. Height velocity remained above baseline for up to eight years. However, this growth response was less than that typically attained in GH-deficient children receiving standard doses of GH therapy. After long-term IGF-1 treatment, most patients do not experience sufficient catch-up growth to bring their height into normal range. This treatment also results in rapid catch-up growth of head circumference and normalization of metabolic abnormalities such as hyperlipidemia and insulin resistance [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         IGF-1 has also been effectively used for patients with GHI caused by mutations in the
         <em>
          IGF1
         </em>
         gene, resulting in increased linear growth and beneficial effects on body composition, including increased bone mineral density [
         <a href="#rid50">
          50,51
         </a>
         ]. (See
         <a class="local">
          'Defects of IGF-1 synthesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety
         </strong>
         – Recombinant IGF-1 may induce hypoglycemia, particularly in younger children and in those with hypoglycemic episodes prior to the initiation of treatment. To avoid this, each dose should be given after a carbohydrate-containing meal or snack [
         <a href="#rid41">
          41
         </a>
         ]. In the study cited above [
         <a href="#rid49">
          49
         </a>
         ], hypoglycemia occurred in 40 percent of subjects and was severe in 9 percent, and 5 percent of the subjects had at least one hypoglycemic seizure. Other side effects included adenotonsillar hypertrophy (22 percent) and intracranial hypertension (4 percent), both of which have been reported with GH treatment [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A few allergic reactions to
         <a class="drug drug_general" data-topicid="9464" href="/z/d/drug information/9464.html" rel="external">
          mecasermin
         </a>
         , including anaphylaxis, have been reported [
         <a href="#rid53">
          53,54
         </a>
         ]. One such patient had negative skin testing to the drug and was treated with a desensitization protocol [
         <a href="#rid54">
          54
         </a>
         ]. Despite these precautions, this patient developed recurrent allergic reactions after three additional weeks of treatment with mecasermin.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H531691809">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114455.html" rel="external">
          "Society guideline links: Growth hormone deficiency and other growth disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12573401">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology and laboratory features
         </strong>
         – Growth hormone insensitivity (GHI) can be caused by loss-of-function mutations in the growth hormone (GH) receptor or in its downstream mediators, including insulin-like growth factor 1 (IGF-1). These rare syndromes are characterized by normal or elevated levels of GH and low levels of IGF-1 (except for mutations of the IGF-1 receptor, in which IGF-1 levels are increased or normal) (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Pathophysiology and clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most short patients with normal GH levels do not have one of these GHI syndromes and are classified as having idiopathic short stature rather than GHI. However, lesser degrees of GH resistance may play a role in idiopathic short stature (
         <a class="graphic graphic_figure graphicRef80626" href="/z/d/graphic/80626.html" rel="external">
          figure 1
         </a>
         ). Most of these patients with idiopathic short stature are not eligible for treatment with recombinant IGF-1. (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5824.html" rel="external">
          "Growth hormone treatment for idiopathic short stature", section on 'Dose adjustment for IGF-1 levels'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Identifying the cause
         </strong>
         – Causes of GHI and their clinical features are listed in the table (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laron syndrome
         </strong>
         – Laron syndrome is the most common cause of GHI and caused by mutations in the GH receptor gene. Affected patients have severe postnatal growth failure, characteristic facies, and metabolic abnormalities (
         <a class="graphic graphic_picture graphicRef80534" href="/z/d/graphic/80534.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_table graphicRef70163" href="/z/d/graphic/70163.html" rel="external">
          table 2
         </a>
         ). Most patients are from populations with Mediterranean or Middle Eastern ancestry (including a population in Ecuador), and a family history of consanguinity is common. (See
         <a class="local">
          'Growth hormone receptor mutations (Laron syndrome)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Laron syndrome should be suspected in patients with severe growth failure and low IGF-1 and insulin-like growth factor-binding protein 3 (IGFBP-3) levels, especially if GH levels are normal or increased, the GH-binding protein (GHBP) level is low, and an IGF-1 generation test is subnormal (
         <a class="graphic graphic_algorithm graphicRef112625" href="/z/d/graphic/112625.html" rel="external">
          algorithm 1
         </a>
         ). The diagnosis should be confirmed through genetic testing where available. These tests can also help to identify and categorize other causes of primary GHI (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           IGF1
          </em>
         </strong>
         <strong>
          gene mutation
         </strong>
         – In patients with marked prenatal growth failure, an
         <em>
          IGF1
         </em>
         gene mutation should be considered. Like patients with GH receptor mutations, these patients will have normal or increased levels of GH and low IGF-1 levels. Unlike patients with GH receptor mutations, the plasma IGFBP-3 level is elevated (
         <a class="graphic graphic_table graphicRef62441" href="/z/d/graphic/62441.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Defects of IGF-1 synthesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cause unknown/partial GHI
         </strong>
         – If the cause of GHI has not been established, we suggest a trial of GH therapy before considering IGF-1 replacement (
         <a class="graphic graphic_algorithm graphicRef112625" href="/z/d/graphic/112625.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Some of these children have partial GHI and may respond to GH (if given at higher doses than for the typical patient with GH deficiency), manifested as increased height velocity and IGF-1 concentrations. If GH is effective, it is preferable to IGF-1. Patients who do not respond can proceed to treatment with IGF-1. (See
         <a class="local">
          'Trial of growth hormone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe GHI
         </strong>
         – For children two years of age or older with severe GHI (defined as height and basal IGF-1 ≤-3 standard deviations [SD], with normal or elevated levels of GH) due to Laron syndrome or most other known defects, we recommend treatment with IGF-1 (
         <a class="drug drug_general" data-topicid="9464" href="/z/d/drug information/9464.html" rel="external">
          mecasermin
         </a>
         ) rather than GH or no treatment (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Hypoglycemia is a common side effect of recombinant IGF-1, particularly in younger children. IGF-1 is ineffective for patients with IGF-1 receptor mutations. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism? Isr J Med Sci 1966; 2:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang P, Girgis R, Little BM, et al. Growth hormone (GH) insensitivity and insulin-like growth factor-I deficiency in Inuit subjects and an Ecuadorian cohort: functional studies of two codon 180 GH receptor gene mutations. J Clin Endocrinol Metab 2008; 93:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arman A, Ozon A, Isguven PS, et al. Novel splice site mutation in the growth hormone receptor gene in Turkish patients with Laron-type dwarfism. J Pediatr Endocrinol Metab 2008; 21:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villela TR, Freire BL, Braga NTP, et al. Growth Hormone insensitivity (Laron syndrome): Report of a new family and review of Brazilian patients. Genet Mol Biol 2020; 42:e20180197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottrell E, Maharaj A, Williams J, et al. Growth Hormone Receptor (GHR) 6Ω Pseudoexon Activation: a Novel Cause of Severe Growth Hormone Insensitivity. J Clin Endocrinol Metab 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993; 68:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods KA, Dastot F, Preece MA, et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997; 82:3529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guevara-Aguirre J, Bautista C, Torres C, et al. Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador. Rev Endocr Metab Disord 2021; 22:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004; 89:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3:70ra13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guevara-Aguirre J, Procel P, Guevara C, et al. Despite higher body fat content, Ecuadorian subjects with Laron syndrome have less insulin resistance and lower incidence of diabetes than their relatives. Growth Horm IGF Res 2016; 28:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laron Z. Consequences of not treating children with laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab 2001; 14 Suppl 5:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laron Z, Kauli R. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment. Growth Horm IGF Res 2016; 28:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeno Y, Hubbard GB, Lee S, et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 2009; 64:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwa V, Fujimoto M, Zhu G, et al. Genetic causes of growth hormone insensitivity beyond GHR. Rev Endocr Metab Disord 2021; 22:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kofoed EM, Hwa V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003; 349:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chia DJ, Subbian E, Buck TM, et al. Aberrant folding of a mutant Stat5b causes growth hormone insensitivity and proteasomal dysfunction. J Biol Chem 2006; 281:6552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwa V, Camacho-Hübner C, Little BM, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res 2007; 68:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfeld RG, Hwa V. The growth hormone cascade and its role in mammalian growth. Horm Res 2009; 71 Suppl 2:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen AC, Nadeau KC, Tu W, et al. Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol 2006; 177:2770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wit JM, de Luca F. Atypical defects resulting in growth hormone insensitivity. Growth Horm IGF Res 2016; 28:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods KA, Camacho-Hübner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996; 335:1363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonapace G, Concolino D, Formicola S, Strisciuglio P. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 2003; 40:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batey L, Moon JE, Yu Y, et al. A novel deletion of IGF1 in a patient with idiopathic short stature provides insight Into IGF1 haploinsufficiency. J Clin Endocrinol Metab 2014; 99:E153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouni M, Castell AL, Rothenbuhler A, et al. Higher methylation of the IGF1 P2 promoter is associated with idiopathic short stature. Clin Endocrinol (Oxf) 2016; 84:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domené HM, Bengolea SV, Martínez AS, et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004; 350:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domené HM, Hwa V, Argente J, et al. Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009; 72:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dauber A, Muñoz-Calvo MT, Barrios V, et al. Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability. EMBO Mol Med 2016; 8:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003; 349:2211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gkourogianni A, Andrade AC, Jonsson BA, et al. Pre- and postnatal growth failure with microcephaly due to two novel heterozygous IGF1R mutations and response to growth hormone treatment. Acta Paediatr 2020; 109:2067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giabicani E, Willems M, Steunou V, et al. Increasing knowledge in IGF1R defects: lessons from 35 new patients. J Med Genet 2020; 57:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Göpel E, Rockstroh D, Pfäffle H, et al. A Comprehensive Cohort Analysis Comparing Growth and GH Therapy Response in IGF1R Mutation Carriers and SGA Children. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binder G. Noonan syndrome, the Ras-MAPK signalling pathway and short stature. Horm Res 2009; 71 Suppl 2:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozzola M, Travaglino P, Marziliano N, et al. The shortness of Pygmies is associated with severe under-expression of the growth hormone receptor. Mol Genet Metab 2009; 98:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gil AP, Kostopoulou E, Karageorgou I, et al. Increased growth hormone receptor (GHR) degradation due to over-expression of cytokine inducible SH2 domain-containing protein (CIS) as a cause of GH transduction defect (GHTD). J Pediatr Endocrinol Metab 2012; 25:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu S, Walenkamp MJ, Lankester A, et al. Growth hormone and insulin-like growth factor I insensitivity of fibroblasts isolated from a patient with an I{kappa}B{alpha} mutation. J Clin Endocrinol Metab 2010; 95:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laron Z, Werner H. Laron syndrome - A historical perspective. Rev Endocr Metab Disord 2021; 22:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martha PM Jr, Rogol AD, Veldhuis JD, et al. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab 1989; 69:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen P, Rogol AD, Weng W, et al. Efficacy of IGF-based growth hormone (GH) dosing in nonGH-deficient (nonGHD) short stature children with low IGF-I is not related to basal IGF-I levels. Clin Endocrinol (Oxf) 2013; 78:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr 2016; 86:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rughani A, Zhang D, Vairamani K, et al. Severe growth failure associated with a novel heterozygous nonsense mutation in the GHR transmembrane domain leading to elevated growth hormone binding protein. Clin Endocrinol (Oxf) 2020; 92:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro L, Chatterjee S, Ramadan DG, et al. Whole-exome sequencing gives additional benefits compared to candidate gene sequencing in the molecular diagnosis of children with growth hormone or IGF-1 insensitivity. Eur J Endocrinol 2017; 177:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosse G, Hilger A, Ludwig M, et al. Targeted Resequencing of Putative Growth-Related Genes Using Whole Exome Sequencing in Patients with Severe Primary IGF-I Deficiency. Horm Res Paediatr 2017; 88:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dauber A. IGF-I Deficiency in the Era of Genomics: Lessons Learned. Horm Res Paediatr 2017; 88:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage MO, Burren CP, Rosenfeld RG. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf) 2010; 72:721.
          </a>
         </li>
         <li class="breakAll">
          Ipsen Biopharmaceuticals. Increlex (mecasermin) injection 10 mg: Important Safety Information. 2019. Available at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/9/2020/04/10140519/Increlex-Full-Prescribing-Information.pdf (Accessed on December 21, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collett-Solberg PF, Misra M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008; 93:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods KA, Camacho-Hübner C, Bergman RN, et al. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000; 85:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Concolino D, Muzzi G, Sestito S, et al. Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation. Eur J Pediatr 2010; 169:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ko MW, Liu GT. Pediatric idiopathic intracranial hypertension (pseudotumor cerebri). Horm Res Paediatr 2010; 74:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torjusen E, Calderon J, Rivkees SA. Anaphylactic reaction to recombinant insulin-like growth factor-I. J Pediatr Endocrinol Metab 2008; 21:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz KA, Assa'ad A, Lierl MB, Backeljauw P. Allergic reaction to mecasermin. Ann Allergy Asthma Immunol 2009; 103:82.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15796 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5916640" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18073295" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Growth hormone (GH) insensitivity and insulin-like growth factor-I deficiency in Inuit subjects and an Ecuadorian cohort: functional studies of two codon 180 GH receptor gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18404972" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Novel splice site mutation in the growth hormone receptor gene in Turkish patients with Laron-type dwarfism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31429861" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Growth Hormone insensitivity (Laron syndrome): Report of a new family and review of Brazilian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34453441" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Growth Hormone Receptor (GHR) 6ΩPseudoexon Activation: a Novel Cause of Severe Growth Hormone Insensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8333769" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Growth curves for Laron syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9360502" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Phenotype: genotype relationships in growth hormone insensitivity syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33047268" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1349669" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15001582" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21325617" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26259979" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Despite higher body fat content, Ecuadorian subjects with Laron syndrome have less insulin resistance and lower incidence of diabetes than their relatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11964019" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Consequences of not treating children with laron syndrome (primary growth hormone insensitivity).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26307357" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19228785" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33029712" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Genetic causes of growth hormone insensitivity beyond GHR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13679528" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Growth hormone insensitivity associated with a STAT5b mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16303763" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Aberrant folding of a mutant Stat5b causes growth hormone insensitivity and proteasomal dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17389811" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19407495" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The growth hormone cascade and its role in mammalian growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16920911" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26670721" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Atypical defects resulting in growth hormone insensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8857020" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14684690" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24243634" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A novel deletion of IGF1 in a patient with idiopathic short stature provides insight Into IGF1 haploinsufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26218795" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Higher methylation of the IGF1 P2 promoter is associated with idiopathic short stature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14762184" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19729943" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26902202" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14657428" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32037650" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pre- and postnatal growth failure with microcephaly due to two novel heterozygous IGF1R mutations and response to growth hormone treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31586944" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Increasing knowledge in IGF1R defects: lessons from 35 new patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31680140" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A Comprehensive Cohort Analysis Comparing Growth and GH Therapy Response in IGF1R Mutation Carriers and SGA Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19407499" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19541519" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The shortness of Pygmies is associated with severe under-expression of the growth hormone receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23426819" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Increased growth hormone receptor (GHR) degradation due to over-expression of cytokine inducible SH2 domain-containing protein (CIS) as a cause of GH transduction defect (GHTD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20080849" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Growth hormone and insulin-like growth factor I insensitivity of fibroblasts isolated from a patient with an I{kappa}B{alpha} mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32964395" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Laron syndrome - A historical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2760171" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22924571" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Efficacy of IGF-based growth hormone (GH) dosing in nonGH-deficient (nonGHD) short stature children with low IGF-I is not related to basal IGF-I levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27884013" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31883394" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Severe growth failure associated with a novel heterozygous nonsense mutation in the GHR transmembrane domain leading to elevated growth hormone binding protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28870985" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Whole-exome sequencing gives additional benefits compared to candidate gene sequencing in the molecular diagnosis of children with growth hormone or IGF-1 insensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29073591" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Targeted Resequencing of Putative Growth-Related Genes Using Whole Exome Sequencing in Patients with Severe Primary IGF-I Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28965112" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : IGF-I Deficiency in the Era of Genomics: Lessons Learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20050859" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20050859" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18165284" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The role of recombinant human insulin-like growth factor-I in treating children with short stature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17192294" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770174" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19517134" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20962512" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pediatric idiopathic intracranial hypertension (pseudotumor cerebri).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18556970" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Anaphylactic reaction to recombinant insulin-like growth factor-I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19663134" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Allergic reaction to mecasermin.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
